Summaries by Inventor Hawkins, William
Hawkins, William ; Spitzer, Dirk
T-016481
— WUSTL Technology 016481 Technology Description Researchers at Washington University in St. Louis have developed an additional targeting strategy to provide more flexibility and improve the bioactivity of the anticancer therapeutic TR3. This strategy targets TR3 to mesothelin, a tumor biomarker fr…
Mesothelin-TR3: targeted TRAIL trimers with superior anticancer activityHawkins, William ; Spitzer, Dirk
T-011885
— WUSTL Technology 011885 Technology Description Researchers at Washington University in St. Louis have developed a strategy to specifically target the anticancer therapeutic TR3 to cancer cells using the mesothelin/MUC16 interaction. Mesothelin is a GPI linked cell surface protein expressed in mes…
TR3: a stabilized TRAIL timer for use as an anticancer therapeuticHawkins, William ; Hotchkiss, Richard ; Spitzer, Dirk
T-007646
— WUSTL Technology 007646 Technology Description Researchers at Washington University in St. Louis (WUSTL) have developed a novel TRAIL (TNF-related apoptosis inducing ligand)-based anticancer drug platform, designated TR3. TRAIL has potent and specific apoptotic activity against tumor cells. Thus,…
